Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Asthma
Interventions
DRUG

pMDI budesonide/formotrol 160/4.5 is in group 1

The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.

DEVICE

Symbicort 160/4.5 plus Aerochamber Plus included in group 2

Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.

Trial Locations (1)

79903

Western Sky Medical Research, El Paso

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Western Sky Medical Research

OTHER